CTSL and COVID-19: Several promising repurposed drugs are undergoing clinical trials for the treatment of COVID-19, e.g., CTSL inhibitor SLV213 (https://clinicaltrials.gov/ct2/show/NCT04843787), which was originally developed as a therapeutic for the treatment of Chagas disease,31 and calpains inhibitor BLD2660 (https://clinicaltrials.gov/ct2/show/results/NCT04334460), which was originally developed for the treatment of fibrotic diseases.